Intrauterine adhesions (IUA) are fibrotic scars that develop within the uterine cavity, often following surgical interventions or infections. The resulting condition, widely referred to as Asherman’s ...
BEDFORD, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study.
BEDFORD, Mass., January 13, 2026--(BUSINESS WIRE)--Rejoni, Inc., a clinical-stage company focused on uterine health, today announced that the U.S. Food and Drug Administration (FDA) has completed its ...
The FDA gave premarket approval to the first medical device for the treatment of women with symptomatic moderate-to-severe intrauterine adhesions, known as Asherman syndrome, maker Womed announced on ...
The uterus may acquire scars that make the walls dense and sticky. This condition is also referred to as intrauterine adhesions or Asherman’s syndrome. The uterus is naturally shaped like a balloon, ...
MONTPELLIER, France--(BUSINESS WIRE)--Womed, the women's health tech company pioneering innovative treatments against challenging uterine pathologies based on a novel polymer material technology, ...
Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study. This announcement marks a ...
Rejoni, Inc., a clinical-stage company focused on uterine health, today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and formally filed the Premarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results